Skip to content

US · HOWL · BIOTECHNOLOGY

Werewolf Therapeutics, Inc. (HOWL) intrinsic value and stock valuation

$0.95as of 2026-11-21 · Mkt cap 19.54M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Werewolf Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values HOWL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HOWL’s statements →

Werewolf Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 werewolftx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-60.82M
20192025
Free cash flow
-$-60.29M
20192025
Total equity
$24.8M-22.6% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$1.89M$19.9M$16.4M$0.00
Operating income-$-60.68M-$-73.59M-$-40.5M-$-56.06M-$-50.09M
Net income-$-60.82M-$-70.52M-$-37.37M-$-53.81M-$-49.98M
EPSd-$-1.3M-$-1.61M-$-1.05M-$-1.86M-$-2.71M
Operating cash flow-$-60.29M-$-56.19M-$-32.61M-$-40.6M-$-42.88M
Capital expenditure$0.00-$-250K-$-770K-$-3.61M-$-500K
Free cash flow-$-60.29M-$-56.44M-$-33.38M-$-44.21M-$-43.37M
Total assets$69.4M$126.9M$174.8M$160.3M$179.3M
Total debt$9.44M$37.1M$51.9M$14.7M$15.7M
Net debt-$-48.52M-$-73.91M-$-82.42M-$-114.63M-$-141.87M
Total equity$24.8M$73.4M$111.4M$122.3M$152.8M
Cash and short-term investments$58M$111M$134.3M$129.3M$157.5M
Income statement
20252024202320222021
Revenue$0.00$1.89M$19.9M$16.4M$0.00
Cost of revenue$1.63M$1.81M$1.76M$2.51M$0.00
Gross profit-$-1.63M$70K$18.2M$13.9M$0.00
Research and development expenses$44.8M$56.4M$41.8M$53.8M$35.3M
Selling, general and administrative expenses$15.9M$19.1M$18.7M$21.5M$14.8M
Other expenses-$-1.63M-$-1.81M-$-1.76M-$-5.32M$0.00
Operating expenses$59M$73.7M$58.7M$70M$50.1M
Cost and expenses$60.7M$75.5M$60.5M$72.5M$50.1M
Interest income$3.11M$6.67M$7.42M$1.91M$100K
Interest expense$5.27M$4.66M$3.14M$0.00$0.00
Depreciation and amortization$1.63M$1.81M$1.76M$2.51M$220K
Ebitda-$-53.91M-$-64.05M-$-32.47M-$-51.3M-$-49.77M
Operating income-$-60.68M-$-73.59M-$-40.5M-$-56.06M-$-50.09M
Total other income/expenses, net-$-140K$3.08M$3.13M$2.25M$100K
Income before tax-$-60.82M-$-70.52M-$-37.37M-$-53.81M-$-49.98M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-60.82M-$-70.52M-$-37.37M-$-53.81M-$-49.98M
Weighted average shares outstanding$46M$43.3M$35.7M$28.9M$18.5M
Weighted average diluted shares outstanding$46.8M$43.9M$35.7M$28.9M$18.5M
Balance sheet
20252024202320222021
Cash and short-term investments$58M$111M$134.3M$129.3M$157.5M
Net receivables$0.00$0.00$1.35M$6.93M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$58.6M$113.1M$138.4M$140.2M$161.1M
Property, plant and equipment, net$9.9M$12.3M$14.9M$17.5M$16.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$900K$1.22M$21M$1.21M$0.00
Total non-current assets$10.8M$13.9M$36.5M$20.1M$18.2M
Total assets$69.4M$126.9M$174.8M$160.3M$179.3M
Accounts payable$750K$3.04M$1.34M$1.22M$2.04M
Short-term debt$1.75M$1.56M$8.28M$2.08M$1.07M
Deferred revenue$0.00$0.00$910K$6.53M$0.00
Total current liabilities$36.2M$15.2M$19.4M$24M$11.9M
Long-term debt$7.68M$35.5M$43.7M$12.6M$14.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.44M$38.4M$44.1M$13.9M$14.6M
Capital lease obligations$7.68M$11M$12.6M$14.7M$15.7M
Total liabilities$44.6M$53.5M$63.5M$37.9M$26.5M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-475.41M-$-414.59M-$-344.07M-$-306.7M-$-252.9M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$24.8M$73.4M$111.4M$122.3M$152.8M
Total investments$900K$1.22M$21M$1.21M$0.00
Total debt$9.44M$37.1M$51.9M$14.7M$15.7M
Net debt-$-48.52M-$-73.91M-$-82.42M-$-114.63M-$-141.87M
Cash flow statement
20252024202320222021
Net income-$-60.82M-$-70.52M-$-37.37M-$-53.81M-$-49.98M
Depreciation and amortization$1.63M$1.81M$1.76M$1.1M$220K
Stock-based compensation$6.25M$8.83M$8.01M$7.4M$4.09M
Change in working capital-$-8.21M$2.53M-$-5.89M$2.54M$2.28M
Accounts receivable$0.00$1.35M$5.58M-$-6.93M$0.00
Inventory$0.00$0.00$0.00$6.93M$0.00
Accounts payable-$-7.5M$3.46M-$-4.33M-$-880K$1.01M
Net cash provided by operating activities-$-60.29M-$-56.19M-$-32.61M-$-40.6M-$-42.88M
Investments in property, plant and equipment$0.00-$-250K-$-770K-$-3.61M-$-500K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-250K-$-770K-$-3.61M-$-500K
Common stock issued$6.03M$23.6M$18.3M$15.7M$111.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.03M$13.1M$58.4M$15.9M$109.4M
Net change in cash-$-54.26M-$-43.36M$25.1M-$-28.3M$66.1M
Cash at end of period$58M$112.2M$155.6M$130.5M$158.8M
Operating cash flow-$-60.29M-$-56.19M-$-32.61M-$-40.6M-$-42.88M
Capital expenditure$0.00-$-250K-$-770K-$-3.61M-$-500K
Free cash flow-$-60.29M-$-56.44M-$-33.38M-$-44.21M-$-43.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Werewolf Therapeutics, Inc.

        Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

        CEO
        Daniel J. Hicklin
        Employees
        14
        Beta
        0.30

        Explore

        Frequently asked questions

        What is the intrinsic value of Werewolf Therapeutics, Inc. (HOWL)?

        InvestorsCraft does not currently publish an intrinsic value for HOWL. How the IC value is calculated.

        Is HOWL undervalued?

        InvestorsCraft does not publish an undervaluation signal for HOWL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.